Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.59 |
| ▸ | FPR2 | P25090 | 3/20 | 0.53 |
| ▸ | LAP3 | P28838 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28214706 | 0.89 | ALDH1A1 (0.88) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL9088587 | 0.83 | ALDH1A1 (1.00) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL20706958 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL15302480 | 0.80 | ALDH1A1 (0.72) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL28824274 | 0.80 | ALDH1A1 (0.72) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL13838843 | 0.80 | ALDH1A1 (0.72) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL13785341 | 0.80 | ALDH1A1 (0.72) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL24710125 | 0.80 | FOLH1 (0.55) | ALDH1A1LMNAMEN1KMT2AFOLH1 | |
| SCHEMBL29179647 | 0.80 | FOLH1 (0.55) | ALDH1A1LMNAMEN1KMT2AFOLH1 | |
| Levacetylleucine SCHEMBL714003 | 0.78 | ALDH1A1 (1.00) | ALDH1A1LMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | ALDH1A1 3177/4885LMNA 2237/4885MEN1 3185/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | ALDH1A1 3177/4885LMNA 2237/4885MEN1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.